Tony Hunter, Brian Druker and John Mendelsohn have won this year’s Tang Prize in biopharmaceutical science for their breakthroughs in developing targeted cancer therapies, the Tang Prize Selection Committee announced yesterday.
Their research and findings of protein tyrosine phosphorylation and tyrosine kinases as oncogenes have led to successful targeted cancer therapies, the committee said.
The three winners, all Americans, have shown how basic science can lead to clinical applications that benefit humankind, said Chang Wen-chang (張文昌), a member of Academia Sinica and the convener of the selection committee.
Photo: CNA
Hunter demonstrated that a mechanism called tyrosine phosphorylation acts as a master on/off switch for a number of key proteins that are critical for successful cancer therapies, the committee said.
Hunter, a professor of biology at the Salk Institute, gave birth to the field of targeted therapies after discovering in 1979 the mechanism of tyrosine phosphorylation and that the oncogene Src is a tyrosine kinase.
The historic discovery paved the way for active research in the following two decades on tyrosine kinase oncogenes, ultimately leading to the development of tyrosine kinase inhibitors (TKIs).
Based on Hunter’s discovery, Druker, the director of Oregon Health & Science University’s Knight Cancer Institute, led the successful clinical trial of a cancer-fighting drug called imatinib.
The drug turned chronic myelogenous leukemia, a cancer that once had a very low survival rate, into a manageable condition.
Gleevec, a brand of imatinib, shuts off oncogenic signals by inhibiting Abl-protein tyrosine kinases as predicted by Hunter’s original research, the committee said.
Gleevec has also been successfully used in the treatment of acute lymphocytic leukemia and certain types of gastrointestinal stromal tumors by inhibiting other tyrosine kinase oncoproteins.
There are more than 26 TKIs that have been approved for clinical use. All of the discoveries have Druker’s first successful trials to thank because they spurred this still burgeoning targeted therapy era, the committee said.
John Mendelsohn, president emeritus of MD Anderson Cancer Center, took another approach to combating cancer.
An alternative way of shutting off the activities of tyrosine kinases on the cell surface (receptor tyrosine kinase) is to develop antibodies against the extracellular domain of the receptor, the committee said.
In such a way, the natural ligand, or growth factor, can no longer bind and the receptor tyrosine kinase is no longer activated. Mendelsohn and his team came up with the idea that antibodies targeting the epidermal growth factor receptor (EGFR) may be an effective strategy for cancer treatment.
Mendelsohn led his team in conducting preclinical research and proceeded to develop the anti-EGFR antibody cetuximab, which eventually won the US Food and Drug Administration’s approval for the treatment of colon cancer and head/neck cancer.
Considering that most countries issue more than five denominations of banknotes, the central bank has decided to redesign all five denominations, the bank said as it prepares for the first major overhaul of the banknotes in more than 24 years. Central bank Governor Yang Chin-lung (楊金龍) is expected to report to the Legislative Yuan today on the bank’s operations and the redesign’s progress. The bank in a report sent to the legislature ahead of today’s meeting said it had commissioned a survey on the public’s preferences. Survey results showed that NT$100 and NT$1,000 banknotes are the most commonly used, while NT$200 and NT$2,000
The Centers for Disease Control (CDC) yesterday reported the first case of a new COVID-19 subvariant — BA.3.2 — in a 10-year-old Singaporean girl who had a fever upon arrival in Taiwan and tested positive for the disease. The girl left Taiwan on March 20 and the case did not have a direct impact on the local community, it said. The WHO added the BA.3.2 strain to its list of Variants Under Monitoring in December last year, but this was the first imported case of the COVID-19 variant in Taiwan, CDC Deputy Director-General Lin Ming-cheng (林明誠) said. The girl arrived in Taiwan on
ANNUAL EVENT: Two massive Pokemon balloons are to be set up in Daan Park, with an event zone operating from 10am to 6pm This year’s Taipei Floral Picnic is to be held at Daan Park today and tomorrow, featuring an exclusive Pokemon Go event, a themed food market, a coffee rave picnic area and stage performances, the Taipei Department of Information and Tourism said yesterday. Two massive Pokemon balloons are to be set up in the park as attractions, with an exclusive event zone operating from 10am to 6pm, it said. Participants who complete designated tasks on-site would have a chance to receive limited-edition souvenirs, it added. People could also try the newly launched game Pokemon Pokopia in the trial area, the department said. Three PokeStops are
South Korea is planning to revise its controversial electronic arrival card, a step Taiwanese officials said prompted them to hold off on planned retaliatory measures, a South Korean media report said yesterday. A Yonhap News Agency report said that the South Korean Ministry of Foreign Affairs is planning to remove the “previous departure place” and “next destination” fields from its e-arrival card system. The plan, reached after interagency consultations, is under review and aims to simplify entry procedures and align the electronic form with the paper version, a South Korean ministry official said. The fields — which appeared only on the electronic form
RSS